Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467695 | 1.00 | TP53 (0.47) | TP53TSHRALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL29847360 | 0.76 | ALDH1A1 (0.57) | TP53TSHRALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL7407565 | 0.76 | CHRNB2 (0.58) | CYP1A2 | |
| SCHEMBL7818285 | 0.76 | CHRNB2 (0.58) | CYP1A2 | |
| SCHEMBL7911780 | 0.76 | CHRNB2 (0.58) | CYP1A2 | |
| SCHEMBL7816212 | 0.76 | CHRNA3 (0.61) | — | |
| SCHEMBL7410204 | 0.76 | CHRNA3 (0.61) | — | |
| SCHEMBL31177832 | 0.75 | ALDH1A1 (0.41) | TP53TSHRALDH1A1CYP3A4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6585152 | 0.75 | CHRNB2 (0.57) | CYP1A2 | |
| Hydrochloric Acid SCHEMBL7827685 | 0.75 | CHRNB2 (0.57) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | TP53 271/4885TSHR 2816/4885ALDH1A1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.